Sex Inequalities in Medical Research: A Systematic Scoping Review of the Literature

Lea Merone, Komla Tsey, Darren Russell, and Cate Nagle

Abstract

Background: Historically, medical studies have excluded female participants and research data have been collected from males and generalized to females. The gender gap in medical research, alongside overarching misogyny, results in real-life disadvantages for female patients. This systematic scoping review of the literature aims to determine the extent of research into the medical research sex and gender gap and to assess the extent of misogyny, if any, in modern medical research.

Methods: Initial literature searches were conducted using PubMed, Science Direct, PsychINFO and Google Scholar. Articles published between January 01, 2009, and December 31, 2019, were included. An article was deemed to display misogyny if it discussed the female aesthetic in terms of health, but did not measure health or could not be utilized to improve clinical practice.

Results: Of the 17 included articles, 12 examined the gender gap in medical research and 5 demonstrated misogyny, assessing female attractiveness for alleged medical reasons. Females remain broadly under-represented in the medical literature, sex and gender are poorly reported and inadequately analyzed in research, and misogynistic perceptions continue to permeate the narrative.

Conclusion: The gender gap and misogynistic studies remain present in the contemporary medical literature. Reasons and implications for practice are discussed.

Keywords: feminism; gender; health disparities; gender gaps; medicine

Background

Amid calls for Australian research policy to align with those in Europe and United States and increase equality in sex and gender recruitment in medical research, the sex and gender gap in medical practice is drawing increasing media attention. Females account for >50% of the global population and, therefore, a significant proportion of the patient population, yet women wait longer than men for both a diagnosis and pain relief, and are more likely to be misdiagnosed or discharged during serious medical events.

Historically, medical studies have excluded female participants and research data have been collected from males and subsequently generalized to females and subsequently generalized to females and subsequently generalized to females and subsequently generalized to females.
those who are intersex and do not have the reproductive anatomy characteristic of female or male. There are several postulated reasons for preferring males in research, including concerns for decreasing fertility or harming pregnancy, researcher bias from predominantly male researchers, and perception of the male as representative of the human species and, therefore, the norm.

The gender gap in medical research, alongside overarching misogyny, results in real-life implications for female patients. The “Yentl syndrome,” named after the central protagonist in the 19th century story by Isaac Beshevis Singer, is the phrase coined by Dr. Bernadette Healy that describes how, for a woman’s illness to be taken seriously, she must prove herself to be as unwell as a male counterpart. Yentl syndrome as a cause of delayed care for female patients is well documented in the medical literature. Lack of research evidence from female patients may result in delay in treatment; applying inappropriate, ineffective, or harmful treatments; or the withholding of effective treatments.

The resulting detriment to women’s health is evidenced in the contemporary literature; recent studies have demonstrated that women with acute myocardial infarction (MI) present with different symptoms to men and are less likely to be identified during angiography than men, simply because they are often underinvestigated and subsequently less likely to be managed appropriately. Six-months after admission for MI, female patients, especially younger women, were more likely to suffer major adverse events and overall mortality.

Androcentricity in medical research has historically disadvantaged and damaged female patients, from inaccurate diagnoses of “hysteria” and related barbaric treatments such as clitoridectomies and extended periods of enforced bedrest, to the more modern discrepancies observed in diagnoses and management of female patients. The hysterical discourse is often used colloquially, with terms such as “mad” and “crazy” used to describe “difficult” women who do not respond to treatment or diagnosis as expected.

Young et al. examined the discourse surrounding patients with endometriosis, determining that the pain and experiences of these patients were often dismissed as psychological. In keeping with this, a recent study in the United States determined an average time to diagnosis of endometriosis from first consultation was 4.4 years and this was shorter in women who were aged <18 years and 40–49 years and those referred to and investigated by gynecologists.

The concept of females being “difficult” is embedded in societally and culturally ingrained misogyny. Historically, the perception of beauty has been used to oppress women, whereby maintenance of fertility and aesthetics was of paramount importance. The use of beauty as a tool of oppression has become known as the “beauty myth” and was analyzed by feminist writer Naomi Wolf in her book “The Beauty Myth: how images of beauty are used against women.” This myth is evident in the medical literature today, highlighted by recent mainstream media controversies over doctors rating the aesthetic attractiveness of their endometriosis patients. Wolf asserts that the “beauty myth” is a tool of oppression and a political weapon against women.

The “hidden curriculum” may be an important contributor to the outcomes of the androcentricty of medical research on the experiences of female patients. The hidden curriculum pertains to the aspects of medicine that are not formally taught to medical students: the attitudes and values collected from their experiences with senior clinicians on the wards and in general practice. Perceptions from androcentric medical research, whereby female patients do not fit the male mould and, therefore, are “difficult” or “mad,” may be passed down through the hidden curriculum to junior staff members, thereby continuing the cycle. In addition, medical students arguably become acculturated to the historically masculine medical environment that demands conformity.

As more is learnt about the gender gap and misogyny in medical research, and the impact this has upon female patients, it is important to determine whether misogyny continues to permeate the narrative in modern medicine. It is also important, while examining misogyny in medical research, to realize that sex and gender are distinct, yet the terms are often used interchangeably. Sex refers to the biological and physiological characteristics that define humans as male, female, or intersex.

Gender, rather, is a societal construct that refers to roles, activities, and behaviors, and encompasses a wide range of identities beyond male, female, and intersex. In this systematic scoping review, we aim to explore the extent of study into sex and gender gaps in the published literature and assess whether misogynistic characterization is prevalent in contemporary medical research.
Methods

Search strategies and study selection
A three-phase approach to searching the literature was employed. Initial literature searches were conducted by one author (L.M.) using PubMed, Science Direct (Elsevier) PsychINFO, and Google Scholar, in line with current recommendations (9). Key words were used for each database and combined with Boolean operators AND and OR. A second search of each database was performed using different terms. All search terms are outlined in Table 1. Finally, a citation search was performed to identify studies that may not have been captured in the search terms.

Inclusion criteria
Selected articles included all peer-reviewed journal publications published between January 01, 2009, and January 01, 2019. Studies were restricted to English language articles, and those where full text was not available were excluded. Opinion pieces, editorials, and nonpeer-reviewed publications were also excluded. An article was deemed to display misogyny if it discussed/assessed the female aesthetic in terms of health, but either did not measure health, or if the research could not be deemed useful or beneficial for clinical practice.

A total of 30 full texts were assessed by two authors using stringent inclusion and exclusion criteria (Table 2); a further 13 were excluded, of these 6 were editorials or reports rather than research, 2 were based on the gender gap in scientists rather than patients, and the remaining 5 examined clinical care and interventions rather than the presence of a gender gap in the literature. A total of 17 articles were included in the qualitative analysis.

Table 1. Search Terms

| Search number | PubMed (MeSH) | Science Direct | PsychINFO | Google Scholar |
|---------------|---------------|----------------|-----------|----------------|
| 1             | Sex           | Sex            | Sex       | Sex            |
|               | Translational medical research | Gender        | Gender    | Gender         |
|               | Biomedical research | Sexism        | Sexism    | Sexism         |
|               | Gender gap    | Research       | Research  | Research       |
|               | Medical research | Gender gap    | Medical   | Gender gap     |
|               |               | Medical research | Medical   | Medical        |
| 2             | Women         | Women          | Women     | Women          |
|               | Aesthetic     | Sexism         | Sexism    | Sexism         |
|               | Disease       | Attractive     | Attractive| Attractive     |
|               | Research      | Aesthetic      | Aesthetic | Aesthetic      |
|               | Attractive    | Research       | Research  | Research       |

Table 2. Inclusion and Exclusion Criteria

| Inclusion criteria | Exclusion criteria |
|--------------------|--------------------|
| Research article   | Opinion piece, editorial, etc. |
| English and available | Non-English or unavailable |
| Examines the gender gap in medical research or focuses on female aesthetics in medicine | Examines the impact of gender on clinical care |
| 2009–2019          | Before 2009        |

Data extraction
The results were merged and duplicates removed using Endnote X9.3. Data were collected from the 17 included articles using a data extraction tool (Table 2) to collect the study name, lead author and year, methods, aims and objectives, and results. Aims and objectives were taken as direct quotes from the articles where possible, to avoid any interpretation bias. Analysis was conducted according to the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist.24

As demonstrated in the PRISMA flow chart (Fig. 1), 2176 articles were identified by the study search, 2146 were excluded due to lack of relevance. Thirty full texts were assessed for eligibility, with 13 excluded as they did not meet the inclusion criteria. Seventeen articles were included in the analysis.

Results
Of the 17 included articles, 12 examined the gender gap in medical research and 5 demonstrated misogyny, assessing female attractiveness for alleged medical reasons. Three studies were reviews of the published literature25–27 defined as collation of all empirical evidence that fits prespecified eligibility criteria,28 nine were cross-sectional analyses29–38 (observational studies of the published literature over a defined time period39), and the five remaining studies were within-subject experimental design.40–43 Of the 12 studies examining gender gaps (Table 3), 11 were conducted in the United States25,26,29–33,35–38 and 1 in Canada.34

The five experimental design studies were the same five studies that demonstrate misogyny (Table 4). These five studies were conducted in the United Kingdom (n = 2),40,41 Poland (n = 2),42,43 and Italy (n = 1).21 Results are presented in Tables 3 and 4.

Three themes were identified: females remain underrepresented in biomedical research, sex and gender are poorly analyzed and reported in research, and several contemporary research articles display ideas that can be construed as misogynistic.
Proportion of females versus males in clinical trials
A total of seven published articles analyzed the proportion of females–males participating in research trials.\(^{25,30-32,34-36}\) Under-representation of women was noted, largely because of discrepancies between specialities, with some specialist fields recruiting more female participants than male participants, and others recruiting fewer females than males. Kong et al. observed that in cell biology, 60% of studies gave no information on the sex of the cells studied.\(^{33}\) Two studies noted that specifically cardiovascular research appeared to under-represent women.\(^{25,32}\)

Reporting and analysis by sex and gender in clinical trials
Six published articles examined the analysis and reporting of results by sex or gender.\(^{26,29,31,33,34,38}\) These articles found that analysis by sex or gender was somewhere in the range of 6%–38%. Sugimoto et al. noted that articles with authors’ with female names were more likely to report results by sex or gender.\(^{38}\)

Examples of misogyny in medical research
Five articles displayed ideas that could be perceived as misogynistic\(^{21,40-43}\) with three of these five studies...
| Study name, authors, year                                                                 | Methods/description                                                                                                                                                                                                 | Specialty       | Study aims/objectives                                                                 | Results                                                                 |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| “Representation of women in randomised controlled trials of cardiovascular disease prevention” Melloni et al. (2010) | Reviewed the literature for female representation. Examined 156 clinical trials of CVD prevention                                                                                                                   | Cardiology      | “To determine female representation over time and by clinical representation”         | 135 (86.5%) of the trials examined recruited both male and female participants, 20 recruited just males, and 1 recruited just females. Proportion of women in the trials increased from 9% in 1970 to 41% in 2006. Enrollment of women in RCTs for CVD has increased but remains low relative to population disease prevalence. Female representation was high for trials for the diseases: hypertension, diabetes, and stroke, and lowest for heart failure, coronary disease, and lipemias. Females were represented in 30% of trials used to produce heart disease prevention guidelines. |
| “Inclusion, analysis and reporting of sex and race/ethnicity in clinical trials: have we made progress?” Geller et al. (2011) | Cross-sectional analysis of the published literature. Identified RCTs in 9 journals through 2009, 86 were eligible for analysis.                                                                                           | Nil specific    | “To determine the current level of compliance with these guidelines for the inclusion, analysis, and reporting of sex and race/ethnicity in federally funded randomized controlled trials and to compare the current level of compliance with that from 2004” | In total, 30/86 were sex specific. Of those that were not, the median enrollment of women was 37%. Seventy-five percent did not report outcomes by sex. Nine studies had fewer than 20% female participants. Only three studies noted their lack of diversity as a limitation. |
| “Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007–2009.” Poon et al. (2013) | Cross-sectional analysis of clinical trials. Evaluated LPCTs and BLAs for women’s participation, 2007–2009.                                                                                                                                                      | Nil specific    | To provide “an update on the current status of the participation of women in late-phase clinical trials (LPCTs) submitted to support the approval of new drugs and biologics by the FDA” | Female participation in LPCTs was 43% (decrease from 52% in 2001) and 57% (increase from 45% 1995–1999) for BLAs. |
| “Sex bias exists in basic science and translational surgical research” Yoon et al. (2014) | Authors reviewed 2347 articles for sex reporting                                                                                                                                                                                                                      | General surgery | To determine “that sex bias exists in surgical research”                              | Sex reporting was poor; for animal studies 22% did not specify sex, and where sex was specified, 84% used male animals only. For cell research, 76% did not report sex, again where sex was reported, 71% were male. For female-prevalent diseases, 44% did not specify sex studied and those that did, only 12% used female animals. In total, 38.1% of studies reported data by sex, 32.2% analyzed results by sex, and 22.9% discussed implications of sex in the results. Few studies included men and women equally. Inclusion and matching of the sexes varied greatly. |
| “Determining if sex bias exists in human clinical research” Mansukhani et al. (2016) | Cross-sectional analysis of published literature. Extracted data from 1303 research articles across five clinical journals                                                                                                                                               | Nil specific    | “To determine if sex bias exists in human surgical clinical research”                 | In total, 38.1% of studies reported data by sex, 32.2% analyzed results by sex, and 22.9% discussed implications of sex in the results. Few studies included men and women equally. Inclusion and matching of the sexes varied greatly. |
| “Mind the gap: sex bias in basic skin research” Kong et al. (2016) | Evaluated skin research publications between 2012 and 2014 to determine whether the sex was disclosed                                                                                                                                                                   | Dermatology     | To “explore how often discovery in cutaneous biology stems from the study of one sex”   | No sex information was provided in 60% of the studies of cells from humans and animals. Where sex was declared, 70% were male. No study analyzed the effect of sex/gender on their results, and when they were considered, it was focused on the biomedical differences alone, despite the fact >50% of studies examined nonpharmacological interventions. Only 6% performed gender/sex subgroup analysis. No article defined sex/gender. No RCT mentioned gender-diverse populations. |
| “Reporting of sex and gender in randomised controlled trials in Canada: a cross-sectional methods study” Welch et al. (2017) | Cross-sectional examination of gender reporting and proportions in the random cross section of 100 articles published in the Canadian medical literature                                                                                                           | Nil specific    | “Provide preliminary assessment of the extent and nature of reporting about sex and/or gender, including whether sex/gender analysis was carried out” | No study analyzed the effect of sex/gender on their results, and when they were considered, it was focused on the biomedical differences alone, despite the fact >50% of studies examined nonpharmacological interventions. Only 6% performed gender/sex subgroup analysis. No article defined sex/gender. No RCT mentioned gender-diverse populations. |

(continued)
| Study name, authors, year | Methods/description | Specialty | Study aims/objectives | Results |
|--------------------------|---------------------|-----------|-----------------------|---------|
| "Participation of women in clinical trials supporting FDA approval of cardiovascular drugs" Scott et al. (2018) | Cross-sectional analysis of published literature. Assessed enrollment of women in 36 drug trials from 2005 to 2015. | Cardiology | “To examine women’s participation and the reported safety and efficacy by gender for pivotal cardiovascular disease (CVD) trials submitted to the U.S. Food and Drug Administration (FDA) supporting marketing applications” | Proportion of women enrolled ranged 22–81% with a mean of 46%. Women were well represented in studies examining hypertension and atrial fibrillation, over-represented for studies exploring pulmonary hypertension and under-represented in heart failure and coronary artery disease studies. |
| "Sex bias in hand surgery research" Kalliainen et al. (2018) | Cross-sectional evaluation of the recent literature for inclusion of both sexes in research and the use of sex as a dependent variable in hand surgery. In total, 386 studies published in 4 journals for 2 years. | Hand surgery | “To provide a jumping-off point for the conversation in the hand-surgery community about sex-based outcomes” | An equal number of males and females were included in clinical studies; however, many individual studies did not include equal numbers of each gender. The female–male ratio depended on the pathology and surgery required. |
| "The more things change, the more they stay the same: a Study to evaluate compliance with inclusion and assessment of women and minorities in randomised controlled trials" Geller et al. (2018) | Cross-sectional analysis of the published literature. Examined 782 RCTs across 14 journals in 2015 | Nil specific | “To investigate current levels of compliance with guidelines for inclusion, analysis and reporting in NIH-funded RCTs and compare the results with those from 2009 and 2004” | In total, 35 studies enrolled just one sex, median enrollment of women in the remaining studies was 46%, however, 15% of the studies enrolled fewer than 30% women. Only 26% reported the effect of sex as a covariate. The NIH guidelines from the NIH revitalization act 1993 have not resulted in significant increases in reporting results by sex. Women volunteered for the research recruitment registry at a slightly greater proportion than that of all portal users. Supports theories that bias against women in clinical recruitment is due to bias rather than women's unwillingness to be involved. Sex-related reporting increased over the years. Articles with female lead authors had greater chance of reporting sex (OR 1.26). In biomedical research, sex remains under-reported (31%). Scarcity of women in science may be related to inadequate reporting of sex in research. |
| "Count me in: using a patient portal to minimise implicit bias in clinical research recruitment" Kannan et al. (2019) | Cross-sectional study offering patients who utilize an online patient portal the opportunity to volunteer for the research recruitment registry (U.S.). | Nil specific | “Determine differences in volunteering to join a research recruitment registry between men and women” | |
| "Factors affecting sex-reporting in medical research; a cross-sectional bibliometric analysis" Sugimoto et al. (2019) | Bibliometric cross-sectional analyses of >1.5 million articles published during 1980–2016 were examined for sex reporting. | Nil specific | To determine the “degree of sex-reporting across health sciences and the role of gender in sex-related reporting.” | |

BLA, biological license application; CVD, cardiovascular disease; LPCT, late phase clinical trial; RCT, randomized controlled trial.
| Study name, authors, year                                                                 | Methods/description                                                                 | Specialty    | Study aims/objectives                                                                 | Results                                                                                                                                                                                                 |
|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “Judging the health and attractiveness of female faces: is the most attractive level of facial adiposity also considered the healthiest?” Coetzee et al. (2011) | Males and females from a university cohort were asked to transform the adiposity in photographs of female’s faces to optimize attractiveness and then optimize health. | Nil specific | “To test if people differentiate between the level of facial adiposity they find attractive and healthy in female faces” | Females determined there is a significant difference between a healthy level of adiposity and an attractive level of adiposity. For males the difference was far smaller. |
| “Attractiveness of women with rectovaginal endometriosis: a case-control study” Vercellini et al. (2013) | Four physicians (two male, two female) were asked to evaluate the attractiveness of women undergoing surgery for endometriosis on a likert scale. Physical examination of the women included measurement of the breast-underbreast ratio. | Gynecology   | “To evaluate the physical attractiveness of women with and without endometriosis”    | Women with rectovaginal endometriosis were deemed by researchers to be more attractive than those with endometriosis of other locations. These women were also leaner, had larger breasts, and earlier coitarche. |
| “Female facial appearance and health” Gray et al. (2012)                                  | In total, 105 female participants were photographed and then undertook a self-reported health questionnaire regarding bouts of rhinovirus or influenza. Observers rated the photographs for femininity, attractiveness, health, makeup and mood. | Nil specific | To determine whether femininity, health, and attractiveness would correlate negatively with bouts of illness | There was a general trend for facial femininity and attractiveness to correlate negatively with bouts of upper respiratory tract illness, but not with gastrointestinal illness. Concluded that facial attractiveness and femininity may indicate a woman’s health history. |
| “Costs of reproduction are reflected in women’s faces: post-menopausal women with fewer children are perceived as more attractive, healthier and younger than women with more children” Marcinkowska et al. (2018) | In total, 571 male and female participants evaluated photographs of the faces of 30 women of varying parity and asked to choose the faces they found most attractive, younger, and healthier. | Nil specific | To determine whether the “high costs of reproduction” are perceived by others when they evaluate facial attractiveness | Women who had given birth to fewer children were judged as more attractive, younger, and healthier by both male and female participants. Examination of historic photos determined that more attractive younger women had higher reproductive success. |
| “Analysis of the visual perception of female breast aesthetics and symmetry: an eye tracking study.” Pietruski et al. (2019) | Eye-tracking technology was utilized for 100 participants (50 male, 50 female) observing images of different female breasts. Attractiveness was determined by duration and location of gaze fixation. | Breast surgery | To “objectively analyse the visual processes taking place during the assessment of female breast aesthetics and symmetry” for “more reliable surgical outcomes” | Key characteristics of gave patterns for males and females were the same. Most fixations were on the nipple/areola area, suggesting it is a key area for symmetry. More attention was paid to lower breast shape than upper breast/chest/clavicle areas. Authors state it is unknown how visual patterns translate to assessment of attractiveness. |
stating that they assess female attractiveness as a marker of health.\textsuperscript{21,40,42} Pietruski et al. conducted an analysis of visual tracking of the aesthetic of breasts, however, also stated their method is potentially flawed in that there is limited evidence as to how visual patterns translate to assessment of attractiveness.\textsuperscript{43}

**Discussion**

This review highlights several issues regarding sex and gender in the medical literature. Females remain broadly under-represented in the medical literature, sex and gender are poorly reported and inadequately analyzed in research, and misogynistic articles continue to permeate the narrative.

**Females are largely under-represented in biomedical research**

Several studies determined that women are largely under-represented in medical research. Geller et al. analyzed 86 randomized controlled trials (RCTs) across 9 journals and found female representation to be just 37\%, with only 3 studies noting the limitations of lack of diversity.\textsuperscript{29}

Perception of the disease, rather than actual sex prevalence, appears to drive the representation of females in medical research.\textsuperscript{44} For diseases that are perceived to affect men more than women, androcentricty dominates the research picture. Melloni et al. examined the representation of women in cardiovascular disease prevention RCTs. Although most studies in Melloni’s analysis recruited both sexes and the proportion of women participants was noted to be increasing, there were still 20 studies noted to have recruited only male participants, versus just 1 study with only female participants recruited. Importantly, female representation was higher in diseases perceived to affect women more, such as hypertension and stroke.\textsuperscript{25}

Similarly, Scott et al. also examined the participation of women in cardiovascular drug trials, and determined that in diseases believed to affect women in greater numbers than men, such as hypertension, atrial fibrillation, and pulmonary hypertension, women were either adequately represented or over-represented. In diseases perceived to affect greater number of men than women, such as coronary disease and heart failure, females were under-represented.\textsuperscript{32} Kalliainen et al. noted that the female–male recruitment ratio in hand surgery research was dependent on the pathology, but the ratios recruited were roughly in keeping with sex prevalence of the disease,\textsuperscript{35} noting a need to increase members of the less-represented sex to enhance statistical power.

The 1993 National Institutes of Health Revitalisation Act recommends that women and men be included in clinical trials based on the sex prevalence of the disease and to provide data on the efficacy of treatment in each sex,\textsuperscript{45} which may help account for the under- and over-representation of females depending on disease. However, the perceptions of sex-related prevalence appear frequently to be outdated; for example, coronary artery disease is the commonest cause of death in both men and women\textsuperscript{46} and women experience greater functional disability and symptoms burden and a higher prevalence of nonobstructive coronary artery disease than men.\textsuperscript{47}

Similarly, women make up 30\% of the gout disease population; however, they make up just 5.3\% of gout clinical drug trial participants.\textsuperscript{30} Geller et al. conducted a cross-sectional study of RCTs across 14 journals published in 2015 and determined that the guidelines from the 1993 National Institutes of Health Revitalisation Act have not resulted in significant increases in reporting results by sex.\textsuperscript{36} Indeed, Poon et al. noted in a similar study that female participation in clinical trials has decreased since the 1990s.\textsuperscript{30}

Not only is it important to acknowledge outdated gender-based beliefs, the representation and participation of women in medical research are important because medical research informs the development of clinical guidelines. Clinical guidelines directly impact the lives of patients, therefore, if there are sex and gender differences in presentation, management, and clinical response to management, it is vital these are described. Melloni et al. conducted an analysis of published RCTs and determined that in clinical trials used to inform guidelines for cardiovascular disease prevention in women, female participation was just 30\%.\textsuperscript{25}

Kannan et al. explored recruitment bias using a cross-sectional study of patients volunteering for research through an online portal and concluded that under-representation of women in clinical trials is not due to the unwillingness of women to volunteer, but rather owing to bias within trial design and recruitment.\textsuperscript{37}

**Sex and gender are poorly reported and analyzed in contemporary biomedical research**

Lack of female representation in research was noted consistently throughout review of the literature, however, another related issue was the lack of sex reporting
or inclusion in analysis of many medical and biomed- 
cial studies. Kong et al. evaluated sex bias in published 
dermatological research, much of which is on nonhu-
mans such as cell lines or animals; 60% of the cellular 
studies from both humans and animals provided no in-
formation regarding sex. Where sex was declared, 70% 
of the cell lines studied were from males.33 

Welch et al. supported this observation in a cross-
sectional study of RCTs in Canada, finding that no 
studies considered the influence of sex and only 6% 
of studies performed a subgroup analysis for sex.54 

Similar findings are noted consistently in other studies, 
and sex reporting appears particularly poor in ani-
mal and cellular studies.26,31,38 Analyses of results by 
sex are seemingly poor across all study types.26,31,34 

Some of the gender discrepancy has been explained 
by Hankivsky et al.; examination of statements sur-
rounding sex and gender inclusion from 45 health-
research funding agencies and 10 sex/gender health 
journals determined there is little consistency in whether 
sex and gender are mentioned in funding and publica-
tion guidelines. There is also significant variation in 
the conceptualization of sex and gender and how re-
searchers address this in research. The criteria set by 
agencies fail to address the complex relationship be-
tween sex and gender and health.27 

Misogyny is evident in the medical research. A total 
of five studies exhibited misogyny. Vercellini et al. uti-
лизирована шкала лайк для врачей с целью субъективно оценить 
привлекательность женщин, подвергшихся хирургии для эндометриоза.21 

Although this publication caused outrage in the global media and across social platforms 
such as Facebook and Twitter,2 it is far from unique. 

Three studies proposed to assess the attractiveness of 
the female face as a measure of health, however, none of them utilized objective measures of health.40–42 

Marcinkowska et al. determined that women with 
higher parity are perceived as less attractive and healthy, 
but the study did not provide information regarding 
objective measures of health from which this con-
clusion was generated.42 A further study by Pietruski 
et al. applied eye-tracking technology to ascertain the 
 attractiveness of female breasts in the context of recon-
structive surgery; however, authors acknowledged that 
the link between lingering gaze and attractiveness is un-
known,43 raising the question of why this study was 
conducted. 

Studies displaying misogyny are problematic for clini-
cal medicine and patient care for several reasons. First, 
they continue to perpetuate the concept of the "beauty 
myth" and the utilization of the female aesthetic as a 
tool of oppression and prejudice. In highlighting fe-
male beauty, the authors of the articles inadvertently 
suggest that patient care should be altered based on 
the aesthetic of the patient. Despite the findings of 
Vercellini et al. that attractive women are more likely 
to have severe endometriosis,21 it is unlikely that this 
will be incorporated into clinical practice given the 
subjective nature of the assessment. 

Consequently, studies that focus on the female 
esthetic add little to the care of women and may be 
deemed unethical. Furthermore, the beauty myth has 
been debunked, evidenced by the evolving nature of 
society’s preference of female aesthetics, from the vo-
luptuous women of the 1940s and 1950s to the emaci-
ated females of the 1970s to 1990s, and finally to the 
contemporary fashion of fitness and athleticism as 
beautiful. 

As Wolf writes, “there is no legitimate justification 
for the beauty myth,” but rather the emphasis on 
beauty is about power and patriarchy, where the 
ingsenior woman is most feared as advancing age is associ-
ated with increased knowledge, power, and respect.20 Pos-
ibly as a result of the beauty myth, women’s identities 
may be entrenched in their physical attractiveness, 
which ensures their vulnerability to external approval.20 

Failure to achieve the gold standards to beauty 
impacts on self-esteem and possibly subsequent suc-
cess.2,48,49 Studies focusing on female attractiveness 
may serve to reinforce false beliefs surrounding beauty 
and increase hostility toward women.50 Hostile sexism 
may lead to perpetuation of the hysterical discourse51 
and increase time to diagnosis and occurrence of mis-
diagnoses.

Although sexism remains present in the medical 
sphere, patient care is compromised. The research gap 
and the publication of misogynistic research may ad-
versely affect female care and contribute to the negative 
perceptions of female hysteria and the gap in time to 
diagnosis experienced by many women. The andro-
centric history of medical research led to assumptions about 
women’s health and response to treatments based solely 
on studies from male bodies.10,17 A rapidly growing 
body of evidence from clinical research demonstrates 
that females and males can differ greatly in their suscep-
tibility and presentation of disease and their response to 
treatment and profile of adverse effects.23 

A more immediate issue with studies that display 

misogyny is the trust patients place in the medical
profession. Women reportedly feel a sense of distrust in the medical profession, with many professing acute awareness that doctors have the power to label them as “anxious” or “depressed”, rather than address their physical pain or symptoms.17

Physicians assessing physical attractiveness as part of a clinical assessment is arguably entering dangerous territory when it comes to the doctor–patient relationship.2 Doctors are bound by the Hippocratic Oath and a set of laws from registering boards, under which the boundary of relations with patients is clear and absolute.52 Rating patient attractiveness is, therefore, both inappropriate and extremely subjective, consequently it must not be allowed to blur the clinical picture.

Other countries have developed research policies to address the sex and gender imbalance in research and to stipulate that sex must be reported; Australia has somewhat lagged on this.1,23 Until we address the gender gap and misogyny in medical research, we run the risk of the health care of female patients remaining substandard to the care of male patients.53 The consequences of neglecting sex and gender differences are wide reaching—including inaccuracies in science, adverse health outcomes, and experiences and cost ineffectiveness.23,54

Limitations
This review has a few limitations, first in that sex and gender are largely considered in binary terms and there is no discussion of intersexuality, nonbinary, transgender, or any others on the gender spectrum because there is very limited literature on gender gaps in these population groups, and the authors highlight a need for further research in this area. Second, only articles from the recent decade were included, this was to allow the review to examine only the most contemporary literature, however, it is likely that more historical review would yield more evidence of misogyny and gaps in gender analysis.

Finally, the definition of misogyny in research was determined by the authors, because there was no literature previously examining this topic in the medical literature, there is no gold-standard way to measure the misogyny of a research article. In much the same way as the Bechdel test for positive female representation within media,55 the authors propose it may be of use to develop a tool to assess misogyny in medical research and to provide guidelines to avoid future publication of misogynistic research.

Conclusions
The gender gap and misogynistic studies, which serve little to improve women’s health, remain present in the contemporary medical literature. There may be several drivers for the gender gaps and misogyny revealed by this scoping review, including outdated perceptions of sex prevalence of diseases, unhelpful discourse surrounding female patients and illness, and the ongoing perpetuation of the beauty myth. The hidden curriculum in medical education may be an important and seemingly unexplored contributor to the outcomes of the androcentricity of medical research on the experiences of female patients.

Author Disclosure Statement
No competing financial interests exist.

Funding Information
No funding was received for this article.

References
1. Cheryl Carcel RN. Launch—A call to action: Sex and gender in health research: Updating policy to reflect evidence, 2019. Available at: https://www.georgeinstitute.org/news/launch-a-call-to-action-sex-and-gender-in-health-research-updating-policy-to-reflect-evidence Accessed December 10, 2019.
2. Chalmers V. Fury over scientific paper that judged women battling endometriosis on their looks 2019. Daily Mail Online. Available at: https://www.dailymail.co.uk/health/article-7360967/Fury-scientific-paper-judged-women-battling-endometriosis-looks.html
3. Merone L. The unattractive truth about misogyny in medicine and medical research, in Croakey. Australia: Croakey Blog, 2019.
4. McGregor AJ, Choo E. Gender-specific medicine: Yesterday’s neglect, tomorrow’s opportunities. Acad Emerg Med 2012;19:861–865.
5. Nabel EG. Coronary heart disease in women—An ounce of prevention. N Engl J Med 2000;343:572–574.
6. Chen EH, Shofer FS, Dean, AJ, et al. Gender disparity in analgesic treatment of emergency department patients with acute abdominal pain. Acad Emerg Med 2008;15:414–418.
7. Naamany E, RD, Zuker-Herman R, et al. Is there gender discrimination in acute renal colic pain management? A retrospective analysis in an emergency department setting. Pain Manag Nurs 2019;20:633–638.
8. Anita Holdcroft. Gender bias in research: How does it affect evidence based medicine? J R Soc Med 2007;100:2–3.
9. Catherine Harper. Intersex. London, UK: Bloomsbury Publishing, 2007.
10. Liu KA, Mager NA. Women’s involvement in clinical trials: Historical perspective and future implications. Pharm Pract (Granada) 2016;14:708.
11. Ah-King M, Barron AB, Herberstein ME. Genital evolution: Why are females still understudied? PLoS Biol 2014;12:e1001851.
12. Beery AK, Zucker I. Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev 2011;35:565–572.
13. Merz CN. The Yentl syndrome is alive and well. Eur Heart J 2011;32:1313–1315.
14. Healy B. The Yentl syndrome. N Engl J Med 1991;325:274–276.
15. Khan E, Brieger D, Amerena J. Differences in management and outcomes for men and women with ST-elevation myocardial infarction. Med J Aust 2018;209:118–123.
16. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med 1999;341:217–225.
17. Jackson G. Pain and Prejudice. 2019. Australia: Allen & Unwin.
18. Young K, Fisher J, Kirkman M. “Do mad people get endo or does endo make you mad?”. Clinicians’ discursive constructions of Medicine and women with endometriosis. Femin Psychol 2018;29:337–356.
19. Soliman AM, Fuldeere M, Snabes MC. Factors associated with time to endometriosis diagnosis in the United States. J Womens Health (Larchmt) 2017;26:788–797.

20. Wolf N. The Beauty Myth 1993: Vintage, USA.

21. Vercellini P, Buggio L, Somigliana E, Barbara G, Viganò P, Fedele L. Attractiveness of women with rectovaginal endometriosis: A case-control study. Fertil Steril 2013;99:212–218.

22. Rajput V, Mookerjee AL, Cagande C. The contemporary hidden curriculum in medical education. MedEdPublish 2017;6:1–13.

23. Wainer Z, Carcol C, Hickey M, et al. Sex and gender in health research: Updating policy to reflect evidence. Med J Aust 2019;212:57–62.e1.

24. Drucker AM, Fleming P, Chan AW. Research techniques made simple: Assessing risk of bias in systematic reviews. J Invest Dermatol 2016;136: e109–e114.

25. Melloni C, Berger J, Wang T, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circulation 2010;131:135–142.

26. Yoon DY, Mansukhani NA, Stubbs VC, Henslowe KB, Woodruff TK, Kibbe MR. Sex bias exists in basic science and translational surgical research. Surgery 2014;156:508–516.

27. Hankivsky O, Springer KW, Hunting G. Beyond sex and gender difference in finding and reporting of health research. Res Integrity Peer Rev 2018;3:6.

28. Kmiec Martinc M, Pieper D, Giatt A, Puljak L. Definition of a systematic review used in overviews of systematic reviews, meta-epidemiological studies and textbooks. BMC Med Res Methodol 2019;19:203.

29. Geller SE, Koch A, Pellettiere B, Carnes M. Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: Have we made progress? J Womens Health 2011;20:315–320.

30. Poon R, Khanijow K, Umarjee S, et al. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007–2009. J Womens Health (Larchmt) 2013;22:604–616.

31. Mansukhani NA, Yoon DY, Teter KA, et al. Determining if sex bias exists in human surgical clinical research. JAMA Surg 2016;151:1022–1030.

32. Scott PE, Unger EF, Jenkins MR, et al. Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol 2018;71:1960–1969.

33. Kong BY, Haugh IM, Schlosser BJ, Getsios S, Paller AS. Mind the gap: Sex and race-related reporting in medical research: A cross-disciplinary bibliometric analysis. Lancet 2019;393:550–559.

34. Sugimoto CR, Ahn YY, Smith E, Macaluso B, Lariviere V. Factors affecting sex-related reporting in medical research: A cross-disciplinary bibliometric analysis. Lancet 2019;393:550–559.

35. Setia MS. Methodology series module 3: Cross-sectional studies. Indian J Med Res 2017;155:265–273.

36. Kalliainen LK, Wisecarver I, Cummings A, Stone J. Sex bias in basic skin research. J Invest Dermatol 2016;136:12–14.

37. Velch V, Doull M, Yoganathan M, et al. Reporting of sex and gender in randomized controlled trials in Canada: A cross-sectional methods study. Res Integrity Peer Rev 2017;2:15.

38. Tsey K, Russell D, Nagle C (2022) Sex inequalities in medical research: a systematic scoping review of the literature. Women’s Health Report 3:1, 49–59, DOI: 10.1089/whr.2021.0083.

39. Wolf N. The Beauty Myth 1993: Vintage, USA.

40. Forbes GB, Collinson LL, Jobe RT, Braun KD, Wise LM. Sexism, hostility toward women, and endorsement of beauty ideals and practices: Are beauty ideals associated with oppressive beliefs? Sex Roles 2007;56:265–273.

41. Gilman Sander HK, Roy Porter, GS Rousseau, Elaine Showalter, Hysteria Beyond Freud. Berkeley: University of California Press, 1993.

42. Australian Health Practitioner Regulation Agency. Medical Board of Australia—Sexual boundaries in the doctor-patient relationship, 2018. Available at: https://www.health.gov.au/products/sexual-boundaries-guidelines.aspx Accessed December 15, 2019.

43. Cheryl Carcel. Medical research community calls time on health gender bias, 2019. Available at: https://www.georgeinstitute.org/media-releases/medical-research-community-calls-time-on-health-gender-bias Accessed December 07, 2019.

44. Diane E Hoffmann AJT. The girl who cried pain: A bias against women and minorities in medical education. MedEdPublish 2017;6:1–13.

45. Mastroianni AC, FR, Federman D. NIH revitalization act of 1993 public law 103–143. Washington, DC: National Academies Press, 1994.

46. Yahagi K, Davis H, Virmani R. Sex differences in coronary artery disease: Pathological observations. Atherosclerosis 2015;239:260–267.

47. Kothawade K, Bairey Merz CN. Microvascular coronary dysfunction in women—Pathophysiology, diagnosis, and management. Curr Probl Cardiol 2011;36:291–318.

48. Buhlmann U, Teachman BA, Naumann E, Fehlinger T, Rief W. The meaning of beauty: Implicit and explicit self-esteem and attractiveness beliefs in body dysmorphic disorder. J Anxiety Disord 2009;23:694–702.

49. Evans PC. “If Only I were Thin Like Her, Maybe I Could be Happy Like Her”: The self-implications of associating a thin female with life success. Psychol Women Q 2003;27:209–214.

50. Forbes GB, Collinson LL, Jobe RT, Braun KD, Wise LM. Sexism, hostility toward women, and endorsement of beauty ideals and practices: Are beauty ideals associated with oppressive beliefs? Sex Roles 2007;56:265–273.

51. Gilman Sander HK, Roy Porter, GS Rousseau, Elaine Showalter, Hysteria Beyond Freud. Berkeley: University of California Press, 1993.

52. Australian Health Practitioner Regulation Agency. Medical Board of Australia—Sexual boundaries in the doctor-patient relationship, 2018. Available at: https://www.health.gov.au/products/sexual-boundaries-guidelines.aspx Accessed December 15, 2019.

53. Cheryl Carcel. Medical research community calls time on health gender bias, 2019. Available at: https://www.georgeinstitute.org/media-releases/medical-research-community-calls-time-on-health-gender-bias Accessed December 07, 2019.

54. Diane E Hoffmann AJT. The girl who cried pain: A bias against women and minorities in medical education. MedEdPublish 2017;6:1–13.

55. Setia MS. Methodology series module 3: Cross-sectional studies. Indian J Dermatol 2016;61:261–264.

56. Coetzee V, Re D, Perrett DJ, Tiddeman BP, Xiao D. Judging the health and attractiveness of female faces: Is the most attractive level of facial adiposity the healthiest? Body Image 2011;8:190–193.

57. Gray AW, Boothroyd LG. Female facial appearance and health. Evol Psychol 2012;10:66–77.

58. Marcinowska UM, Little AC, Galbarczyk A, Nenko I, Klimek M, Jasieniska G. Costs of reproduction are reflected in women’s faces: Post-menopausal women with fewer children are perceived as more attractive, healthier and younger than women with more children. Am J Phys Anthropol 2018;165:589–593.

59. Pietruski P, Paskal W, Paskal AM, Jaworowski J, Paluch L, Nosczynz B. Analysis of the visual perception of female breast aesthetics and symmetry: An eye-tracking study. Plast Reconstr Surg 2019;144:1257–1266.

60. Feldman S, Ammar W, Lo K, Trepman E, van Zuylen M, Etzioni O. Quantifying sex bias in clinical studies at scale with automated data extraction. JAMA Netw Open 2019;2:e196700.

Cite this article as: Merone L, Tsey K, Russell D, Nagle C (2022) Sex inequalities in medical research: a systematic scoping review of the literature. Women’s Health Report 3:1, 49–59, DOI: 10.1089/whr.2021.0083.

Abbreviations Used
- BLA = biological license application
- CVD = cardiovascular disease
- FDA = Food and Drug Administration
- LPCT = late phase clinical trial
- MI = myocardial infarction
- PRISMA = preferred reporting items for systematic reviews and meta-analysis
- RCT = randomized controlled trial

Publish in Women’s Health Reports
- Immediate, unrestricted online access
- Rigorous peer review
- Compliance with open access mandates
- Authors retain copyright
- Highly indexed
- Targeted email marketing